Seattle Met Magazine recently interviewed CVI Director, Dr. Nora Disis, and CVI Director of Clinical Trials, Dr. Shaveta Vinayak on our recent publication in JAMA Oncology of our Phase I clinical trial with our HER2 ICD DNA vaccine tested in individuals with HER2+ advanced-stage breast cancer. The study showed that the vaccines are safe (very few side effects) and 75-85% of patients (depending on dose) with advanced stage breast cancer were alive 10 years after vaccination. This vaccine is now in a multinational randomized Phase II clinical trial for breast cancer.
You can read the full article here: https://www.seattlemet.com/health-and-wellness/2023/01/breast-cancer-vaccine-research-uw-medicine-fred-hutch
Comments